Literature DB >> 27222860

Microarray data on altered transcriptional program of Phgdh-deficient mouse embryonic fibroblasts caused by ʟ-serine depletion.

Momoko Hamano1, Tomoko Sayano2, Wataru Kusada3, Hisanori Kato4, Shigeki Furuya5.   

Abstract

Inherent ʟ-Ser deficiency culminates in intrauterine growth retardation, severe malformation of multiple organs particularly the central nervous system, and perinatal or early postnatal death in human and mouse. To uncover the molecular mechanisms underlying the growth-arrested phenotypes of l-Ser deficiency, we compared gene expression profiles of mouse embryonic fibroblasts deficient in 3-phosphoglycerate dehydrogenase (Phgdh), the first enzyme of de novo ʟ-Ser synthetic pathway, between ʟ-Ser-depleted and -supplemented conditions. The datasets (CEL and CHP files) from this study are publicly available on the Gene Expression Omnibus repository (accession number GEO: GSE55687).

Entities:  

Keywords:  Inborn error; Microarray; Neu-Laxova syndrome; PHGDH; Serine

Year:  2016        PMID: 27222860      PMCID: PMC4865675          DOI: 10.1016/j.dib.2016.04.052

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data The gene expression data list the significantly affected genes by reduced ʟ-Ser availability in Phgdh-deficient mouse embryonic fibroblasts. Enriched GO terms and phenotypically relevant gene networks provide insight into altered cholesterol metabolism and stress responses elicited by l-Ser deficiency in embryonic fibroblasts. The data suggest that Phgdh-deficient mouse embryonic fibroblasts serve as a valuable mouse cellular model for human inborn ʟ-Ser deficiency including Neu-Laxova syndrome.

Data

Table 1 of DAVID analysis shows that cholesterol/sterol biosynthetic/metabolic process was enriched GO terms in the biological process (BP) of the down-regulated 381 genes, whereas apoptosis/cell death, amino acid biosynthetic process, tRNA aminoacylation, cell cycle arrest, and transcription were major significantly enriched GO terms in the up-regulated 560 genes. Ingenuity Pathway Analysis (IPA) determined top-ranked networks in the down-regulated genes (Fig. 1A) and the up-regulated genes (Fig. 1B). A network containing genes involved in the cholesterol metabolic process including Hmgcs1, Insig, Hmgcr, and Ldlr, was markedly diminished in the down-regulated genes, while the activation of a network containing stress-responsive Atf4Atf3Ddit3 (CHOP) axis was most prominently in the up-regulated genes.
Table 1

Enriched GO terms in mRNA transcripts of Phgdh-deficient MEFs elicited by ʟ-Ser depletion.

TermCount%P-valueQ-value

DownGO:0006695 Cholesterol biosynthetic process62.01.46E–050.018
GO:0008203 Cholesterol metabolic process82.65.70E–050.035
GO:0016126 Sterol biosynthetic process62.05.72E–050.024
GO:0016125 Sterol metabolic process82.61.05E–040.033
UpGO:0042981 Regulation of apoptosis338.53.21E–085.30E–05
GO:0043067 Regulation of programmed cell death338.54.29E–083.55E–05
GO:0010941 Regulation of cell death338.54.89E–082.70E–05
GO:0006916 Anti-apoptosis112.87.70E–060.003
GO:0008652 Cellular amino acid biosynthetic process82.12.00E–050.007
GO:0044271 Nitrogen compound biosynthetic process194.92.56E–050.007
GO:0043038 Amino acid activation82.12.70E–050.006
GO:0006418 tRNA aminoacylation for protein translation82.12.70E–050.006
GO:0043039 tRNA aminoacylation82.12.70E–050.006
GO:0043066 Negative regulation of apoptosis164.16.84E–050.014
GO:0006399 tRNA metabolic process112.86.92E–050.013
GO:0043069 Negative regulation of programmed cell death164.18.65E–050.014
GO:0060548 Negative regulation of cell death164.19.00E–050.013
GO:0010557 Positive regulation of macromolecule biosynthetic process256.41.06E–040.015
GO:0007050 Cell cycle arrest82.11.11E–040.014
GO:0034976 Response to endoplasmic reticulum stress61.51.25E–040.015
GO:0012501 Programmed cell death235.91.42E–040.015
GO:0008219 Cell death246.21.45E–040.015
GO:0006357 Regulation of transcription from RNA polymerase II promoter276.91.70E–040.016
GO:0031328 Positive regulation of cellular biosynthetic process256.41.96E–040.018
GO:0045449 Regulation of transcription6717.21.97E–040.017
GO:0016265 Death246.22.03E–040.017
GO:0009891 Positive regulation of biosynthetic process256.42.25E–040.018
GO:0030968 Endoplasmic reticulum unfolded protein response51.32.72E–040.020
GO:0034620 Cellular response to unfolded protein51.32.72E–040.020
GO:0006915 Apoptosis225.72.99E–040.021
GO:0006355 Regulation of transcription, DNA-dependent4812.33.68E–040.025
GO:0045935 Positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process235.94.06E–040.026
GO:0051252 Regulation of RNA metabolic process4812.35.20E–040.033
GO:0009309 Amine biosynthetic process82.15.27E–040.032
GO:0051173 Positive regulation of nitrogen compound metabolic process235.96.16E–040.036
Fig. 1

Phenotypically relevant gene networks enriched in Phgdh-deficient MEFs under ʟ-Ser-depleted condition. Gene lists were analyzed by the Ingenuity Pathway Analysis software to identify the top phenotypically relevant gene networks in down-regulated genes (A) and up-regulated genes (B). The networks are displayed graphically as nodes (genes/proteins) and edges (biological interactions between the nodes). The node color intensity indicates the degree of down- (green) or up- (red) regulation. Nodes are displayed using various shapes representing the functional class of the gene product. Edges are displayed with various labels that present the biological nature of interactions between the nodes as follows: A, activation; B, binding; E, expression; I, inhibition; LO, localization; P, phosphorylation/dephosphorylation; PD, protein–DNA binding; PR, protein–mRNA binding; PP, protein–protein binding; T, transcription. Straight lines indicate direct interactions, and dashed lines indicate indirect interactions. Edges without a label represent binding only.

Experimental design, materials and methods

Cells

Phgdh-deficient MEFs were established from individual E13.5 embryos of Phgdh KO mice and maintained as described [1], [2]. To deplete ʟ-Ser, the complete DMEM medium was replaced with Eagle׳s Minimum Essential medium lacking ʟ-Ser and other non-essential amino acids with Earle׳s salts (EMEM; Wako Pure Chemical Industries Ltd.) supplemented with 1% FBS and 10 µg/ml gentamicin [1], [2]. When supplemented ʟ-Ser, 400 µM ʟ-Ser was added to this 1% FBSEMEM medium.

Microarray analysis

Total RNA was extracted using the RiboPure kit (Thermo Fisher Scientific, Waltham, MA USA) after a 6 h incubation under ʟ-Ser-depleted or -supplemented conditions as described [1]. cDNA amplification and labeling, and chip hybridization were carried out as described [1]. After washing, the arrays were scanned with a GeneChipScanner (Affymetrix), and the scans data were processed using the GeneSuite software (Affymetrix). Three biological replicates for each treatment were directly compared.

Data processing and statistical analysis

The data in .CEL files were transferred to GeneSpring 8.0 software (Agilent Technologies). After normalization to its median value, filtration was performed based on the following criteria: (i) scaled intensity>100 under at least one condition; (ii) false discovery rate, q<0.01; and (iii) absolute value of fold change (ʟ-Ser-depleted condition/ʟ-Ser-supplemented) >2.0 or <0.5.

GO term enrichment and pathway analysis

Significantly differentially expressed genes were analyzed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) to calculate GO term enrichments in the biological process category at all levels [3]. Enriched GO terms (Benjamini–Hochberg correction:Q-value<0.05) were deemed significant. Phenotypically relevant gene networks of significantly differentially expressed genes were analyzed using the web-based expression analysis program Ingenuity Pathways Analysis (http://www.ingenuity.com).
Subject areaBiology
More specific subject areaMolecular Biology, Nutritional Biochemistry
Type of dataTable, Figure
How data was acquiredMicroarray data generated on Affymetrix Mouse Genome 430 2.0 GeneChip Array
Data formatAnalyzed
Experimental factorsComparison of gene expression profiles of Phgdh-deficient embryonic fibroblasts between ʟ-Ser-supplemented and -depleted conditions
Experimental featuresRNA isolation, global gene expression analysis, and bioinformatics analyses using IPA and DAVID
Data source locationLaurel, MD, USA
Data accessibilityDataset is within this article and available in the Gene Expression Omnibus with accession number GEO: GSE55687.
  3 in total

1.  DAVID: Database for Annotation, Visualization, and Integrated Discovery.

Authors:  Glynn Dennis; Brad T Sherman; Douglas A Hosack; Jun Yang; Wei Gao; H Clifford Lane; Richard A Lempicki
Journal:  Genome Biol       Date:  2003-04-03       Impact factor: 13.583

2.  L-serine deficiency caused by genetic Phgdh deletion leads to robust induction of 4E-BP1 and subsequent repression of translation initiation in the developing central nervous system.

Authors:  Tomoko Sayano; Yuriko Kawakami; Wataru Kusada; Takeshi Suzuki; Yuki Kawano; Akihiro Watanabe; Kana Takashima; Yashiho Arimoto; Kayoko Esaki; Akira Wada; Fumiaki Yoshizawa; Masahiko Watanabe; Masahiro Okamoto; Yoshio Hirabayashi; Shigeki Furuya
Journal:  FEBS J       Date:  2013-02-24       Impact factor: 5.542

3.  Adaptive response to l-serine deficiency is mediated by p38 MAPK activation via 1-deoxysphinganine in normal fibroblasts.

Authors:  Tomoko Sayano; Yuki Kawano; Wataru Kusada; Yashiho Arimoto; Kayoko Esaki; Momoko Hamano; Miyako Udono; Yoshinori Katakura; Takuya Ogawa; Hisanori Kato; Yoshio Hirabayashi; Shigeki Furuya
Journal:  FEBS Open Bio       Date:  2016-03-03       Impact factor: 2.693

  3 in total
  1 in total

1.  Enhanced vulnerability to oxidative stress and induction of inflammatory gene expression in 3-phosphoglycerate dehydrogenase-deficient fibroblasts.

Authors:  Momoko Hamano; Yurina Haraguchi; Tomoko Sayano; Chong Zyao; Yashiho Arimoto; Yui Kawano; Kazuki Moriyasu; Miyako Udono; Yoshinori Katakura; Takuya Ogawa; Hisanori Kato; Shigeki Furuya
Journal:  FEBS Open Bio       Date:  2018-05-08       Impact factor: 2.693

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.